Results 11 to 20 of about 7,263 (276)

A Case of Possible Infusion-Related Reactions Caused by Palonosetron

Case Reports in Oncology
Introduction: An infusion-related reaction (IRR) is an adverse event that typically occurs when cytotoxic drugs or monoclonal antibodies are administered.
Toru Kadono, Hiroyuki Kodama, Hiroki Yukami, Toshifumi Yamaguchi, Hiroki Nishikawa   +4 more
doaj   +2 more sources

A study to assess the effect of pretreatment with intravenous palonosetron in preventing pain on propofol injection

Journal of Medical Science, 2023
Background. Propofol is widely used for induction, maintenance of anaesthesia and possess many characteristics of an ideal intravenous anaesthetic agent. It is known to cause severe, sharp, stinging or burning pain on injection which is considered to be
Nethra Surhonne, Chaithali Hebri, Sudeesh Kannan   +2 more
doaj   +2 more sources

Comparative evaluation of ondansetron, palonosetron, and dexamethasone for antiemetic prophylaxis in cesarean section under spinal anaesthesia

Asian Journal of Medical Sciences
Background: Spinal anesthesia is the most common regional anesthesia used to provide surgical anesthesia for cesarean section. Nausea and vomiting are common symptoms experienced by patients undergoing cesarean section. Aims and Objectives: The aim of
Vankudoth Bhaskar , Jitendra Agrawal , Ankita Gupta , Ashish Mohan M   +3 more
doaj   +2 more sources

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study

Frontiers in Pharmacology, 2022
Objective: To test the hypothesis that the single use of fosaprepitant is not inferior to the use of palonosetron as antiemetic prophylaxis in the first 48 h after surgery in women undergoing laparoscopic cholecystectomy.Method: Eighty-eight nonsmoking ...
Estêvão Luiz Carvalho Braga, Nubia Verçosa, Ismar Lima Cavalcanti   +2 more
doaj   +2 more sources

Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Cisplatin (CDDP)-induced nephrotoxicity is the most important complication of CDDP treatment. 5-Hydroxytryptamine type 3 receptor antagonists (5-HT3RAs) are widely used to prevent chemotherapy-induced nausea and vomiting (CINV).
Miho Takemura, Kenji Ikemura, Masayoshi Kondo, Fumihiro Yamane, Mikiko Ueda, Masahiro Okuda   +5 more
doaj   +2 more sources

5-HT₃ receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta-analysis. [PDF]

Int J Gynaecol Obstet
Abstract Background Gynecological surgery is generally associated with a high risk of postoperative nausea and vomiting (PONV), for which a combination of antiemetic therapies is advised, but adherence to these protocols is often low. Given the current reality, a preferred 5‐HT3 receptor antagonist for preventing PONV as a result of gynecological ...
Xu H, Rong L, Yang S, Xing J, Dong H, Liu H, Chen X, Liu L.   +7 more
europepmc   +2 more sources

Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study [PDF]

Journal of Geriatric Oncology, 2023
Luigi Celio, Rupert Bartsch, Matti Aapro
openalex   +2 more sources

Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. [PDF]

Int J Mol Sci
Serotonin or 5-hydroxytryptamine (5-HT) has been implicated in promoting cancer cell growth by acting on 5-HT receptors, such as 5-HT1 and 5-HT2 receptors. However, the role of 5-HT3 receptor antagonists in gastric cancer cell lines remains unclear. This
Yoo YC, Lin L, Lee S, Shin YR, Oh JE, Kim NY.   +5 more
europepmc   +2 more sources

Netupitant/Palonosetron [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, James, Leonard, Danial E, Baker   +2 more
openaire   +3 more sources

Palonosetron versus tropisetron with dexamethasone for prevention of postoperative nausea and vomiting in pediatric adenotonsillectomy: a single center, randomized controlled trial. [PDF]

Front Med (Lausanne)
Chen H, Sun L, Zheng J, Gu H.
europepmc   +3 more sources